Landos Biopharma, Inc.
LABPDelisted May 23, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785345
Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.
Q2 2024 vs. Q1 2024
How the institutions holding Landos Biopharma, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 16 | 0 | −16 |
| Shares | 1.62M | 0 | −1.62M (−100.0%) |
| Value | $34.9M | $0 | −$34.9M (−100.0%) |
New holders (0)
Institutions that held Landos Biopharma, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
None.
Sold out (16)
Institutions that held Landos Biopharma, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Perceptive Advisors LLC | 1,486,991 | $31.9M |
| Deltec Asset Management LLC | 50,000 | $1.07M |
| Renaissance Technologies LLC | 18,890 | $406.0K |
| Macquarie Group Ltd | 14,718 | $316.0K |
| Virtu Financial LLC | 14,537 | $313.0K |
| Geode Capital Management, LLC | 12,604 | $271.0K |
| PenderFund Capital Management Ltd. | 9,300 | $270.8K |
| Black Maple Capital Management LP | 10,405 | $223.5K |
| UBS Group AG | 4,084 | $87.7K |
| Tower Research Capital LLC (TRC) | 896 | $19.2K |
| Acadian Asset Management LLC | 134 | $2.00K |
| JPMorgan Chase & Co | 59 | $1.27K |
| Royal Bank of Canada | 61 | $1.00K |
| Morgan Stanley | 13 | $279 |
| Cornerstone Planning Group LLC | 12 | $267 |
| Wells Fargo & Company | 10 | $215 |